-75%

est. 2Y upside i

HealthcareSeries A

Modulo is a Biotech company working to reprogram the brain’s immune system to cure neurodegenerative disorders.

Rank

#2670

Sector

Biotechnology

Est. Liquidity

~5Y

Data Quality

Data: Medium

Modulo Bio presents a high-risk, potentially high-reward equity opportunity.

Last updated: March 10, 2026

Bull (10%)+350%

Modulo Bio's lead candidate, MOD 001, successfully completes IND-enabling studies and receives IND approval, followed by promising early clinical data (e.g., Phase 1). This de-risking attracts a major pharmaceutical partner for a lucrative acquisition or significant licensing deal, pushing valuation to $540M+.

Base (45%)+75%

Modulo Bio continues to advance MOD 001 through IND-enabling studies, potentially submitting an IND application within the 2-year horizon. The proprietary Neuroimmune Platform gains further validation, leading to a modest valuation increase to approximately $210M, reflecting preclinical de-risking and platform potential.

Bear (45%)-80%

MOD 001 faces significant setbacks or delays in IND-enabling studies, or a dominant incumbent's competing neuroimmune therapy demonstrates superior efficacy. This leads to a down round or failure to secure further funding, resulting in a valuation collapse to $24M or less, severely impacting common stock value.

Est. time to liquidity~5.0 years

Preference Stack Risk

high

Investors hold $23M in liquidation preferences. In an exit at or below $23M, common stock would receive nothing. At the estimated current valuation of $120M, investors would receive their $23M first, leaving $97M for common shareholders.

Dilution Risk

high

As a preclinical biotech with very high capital intensity, Modulo Bio will require several more significant funding rounds, leading to substantial future dilution for existing equity holders.

Secondary Liquidity

none

Given its early stage and private status, there is currently no active secondary market for Modulo Bio's equity.

Other — 1 role

  • Careers · Please reach out and let us know more about you and what you’re looking for.
View all 1 open roles at Modulo →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Modulo's data — designed to show you've done your homework.

  • 1

    “Given the high incumbent threat from large pharma, how does Modulo Bio plan to differentiate MOD 001 and its Neuroimmune Platform to secure market share or a strategic partnership?”

  • 2

    “With MOD 001 still in IND-enabling studies, what are the key milestones and timelines for entering human clinical trials, and how is the company mitigating the significant risks associated with this transition?”

  • 3

    “Considering the very high capital intensity of biotech, what is the company's long-term funding strategy beyond the current stage, and how does it plan to manage potential future dilution for employees?”

Community

Valuation Sentiment

Our model estimates -75% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.